改良释放型氢化可的松治疗先天性肾上腺增生症
这项3期随机研究比较改良释放型氢化可的松(MR-HC)与标准糖皮质激素治疗成人先天性肾上腺增生症(CAH),主要终点24小时17OHP SDS变化未达统计学意义,但MR-HC在4周和12周及6个月特定时段显示更好的生化控制,且患者报告获益包括月经恢复和妊娠。
要点
- MR-HC在4周和12周降低17OHP SDS优于标准治疗。
- 6个月时MR-HC组09:00血清17OHP达标率91% vs 标准组71%。
- MR-HC组报告月经恢复和妊娠,标准组无此获益。
核心结论
- MR-HC改善成人CAH的生化疾病控制,并随时间减少类固醇剂量且患者报告获益。
研究设计与样本
- 6个月随机3期研究比较MR-HC与标准糖皮质激素,随后进行单臂MR-HC扩展研究。
- 3期研究招募122例成人CAH患者。
主要发现
- 3期研究6个月时主要终点未达统计学意义。
- MR-HC组17OHP SDS在4周(P = .007)和12周(P = .019)更低,6个月时07:00至15:00时段也更低(P = .044)。
- 09:00血清17OHP控制(< 1200 ng/dL)的患者比例:基线52%,6个月时MR-HC组91% vs 标准组71%(P = .002),扩展研究18个月时MR-HC组80%。
- 氢化可的松中位日剂量:基线25 mg,6个月时标准组31 mg、MR-HC组30 mg,18个月后MR-HC组20 mg。
- 3期研究发生3次肾上腺危象(MR-HC组无),扩展研究发生4次。
临床怎么用
- MR-HC可考虑用于改善成人CAH的生化控制并可能减少氢化可的松剂量。
- MR-HC可能带来患者报告的获益如月经恢复和妊娠。
局限性
- 3期研究6个月时主要终点未达统计学意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Standard glucocorticoid therapy in congenital adrenal hyperplasia (CAH) regularly fails to control androgen excess, causing glucocorticoid overexposure and poor health outcomes. OBJECTIVE: We investigated whether modified-release hydrocortisone (MR-HC), which mimics physiologic cortisol secretion, could improve disease control. METHODS: A 6-month, randomized, phase 3 study was conducted of MR-HC vs standard glucocorticoid, followed by a single-arm MR-HC extension study. Primary outcomes were change in 24-hour SD score (SDS) of androgen precursor 17-hydroxyprogesterone (17OHP) for phase 3, and efficacy, safety and tolerability of MR-HC for the extension study. RESULTS: The phase 3 study recruited 122 adult CAH patients. Although the study failed its primary outcome at 6 months, there was evidence of better biochemical control on MR-HC, with lower 17OHP SDS at 4 (P = .007) and 12 (P = .019) weeks, and between 07:00h to 15:00h (P = .044) at 6 months. The percentage of patients with controlled 09:00h serum 17OHP (< 1200 ng/dL) was 52% at baseline, at 6 months 91% for MR-HC and 71% for standard therapy (P = .002), and 80% for MR-HC at 18 months' extension. The median daily hydrocortisone dose was 25 mg at baseline, at 6 months 31 mg for standard therapy, and 30 mg for MR-HC, and after 18 months 20 mg MR-HC. Three adrenal crises occurred in phase 3, none on MR-HC and 4 in the extension study. MR-HC resulted in patient-reported benefit including menses restoration in 8 patients (1 on standard therapy), and 3 patient and 4 partner pregnancies (none on standard therapy). CONCLUSION: MR-HC improved biochemical disease control in adults with reduction in steroid dose over time and patient-reported benefit.
引用
- Merke DP, Mallappa A, Arlt W, et al. Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2021. PMID: 33527139. doi:10.1210/clinem/dgab051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。